Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou, 310016, Zhejiang Province, China.
Clin Exp Med. 2020 Nov;20(4):609-614. doi: 10.1007/s10238-020-00643-2. Epub 2020 Jul 10.
To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017. A total of 1410 patients were included in the study and divided into four groups according to different PPIs: group A (pantoprazole sodium enteric-coated capsules, 352 cases), group B (esomeprazole magnesium enteric-coated tablets, 462 cases), group C (pantoprazole sodium enteric-coated tablets, 392 cases) and group D (rabeprazole sodium enteric-coated tablets, 204 cases). The eradication rate of Hp and cost-saving in each group were then compared. There were no significant differences of gender (P = 0.526) and age (P = 0.366) between each Hp treatment regimen. The eradication rates of groups A, B, C and D were 91.48%, 89.83%, 86.73% and 90.69%, respectively. No statistical differences of Hp eradication rates were observed between each group yet (P > 0.05). However, the cost of group A was the lowest. In the present study, the Hp eradication rates between different PPIs regimens were similar in treating Hp infection. Nevertheless, the point in favor of pantoprazole capsules is the slightly higher Hp eradication rate and lower drug cost than other PPIs, which provides a significant evidence for the clinical medication decision in treating Hp infection.
为了评估不同质子泵抑制剂（PPIs）联合铋四联方案治疗幽门螺杆菌（Hp）的疗效和经济学效果，采用回顾性分析方法，收集我院消化内科门诊 2017 年 1 月至 6 月接受含铋四联方案（PPI+阿莫西林+呋喃唑酮+果胶铋）治疗的 Hp 阳性患者。共纳入 1410 例患者，根据不同 PPI 分为 4 组：A 组（泮托拉唑钠肠溶片，352 例）、B 组（埃索美拉唑镁肠溶片，462 例）、C 组（泮托拉唑钠肠溶片，392 例）和 D 组（雷贝拉唑钠肠溶片，204 例）。比较各组 Hp 根除率和成本节约。各组性别（P=0.526）和年龄（P=0.366）差异无统计学意义。A、B、C、D 组 Hp 根除率分别为 91.48%、89.83%、86.73%和 90.69%，差异无统计学意义（P>0.05）。但 A 组的成本最低。本研究表明，不同 PPI 方案治疗 Hp 感染的 Hp 根除率相似，但泮托拉唑胶囊的优势在于 Hp 根除率略高，药物成本低于其他 PPI，为治疗 Hp 感染的临床用药决策提供了重要依据。
